Figure 2
From: Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer
Cellular distribution of p21 in C13* and OV2008 cells and its alteration after 3-week of continuous cisplatin treatment. (A) Localization of p21 in C13* (upper panels), OV2008 (upper middle panels), C13*/DDP (lower middle panels) and OV2008/DDP (lower panels) cells. (B) Percentage of cytoplasmic p21 positive cells. (C) Comparison of cytoplasmic p21 between C13* and C13*/DDP, and between OV2008 and OV2008/DDP. (*, p < 0.05; **, p < 0.01).